Publication

Required Evidence for Clinical Applications of Liquid Biopsy Using Especially CTCs in Lung Cancer

Tamminga, M. & Groen, H. J. M., Jun-2020, In : Applied Sciences. 10, 11, 9 p., 3704.

Research output: Contribution to journalReview articleAcademicpeer-review

As therapies have become more and more dependent on tumor as well as patient characteristics, obtaining tumor material has become of great importance. Liquid biopsies hold much potential as shown by a large amount of evidence across several studies. Clinical applications for circulating tumor cells (CTCs) are unfortunately still lacking. In part this is due to a lack of studies comparing liquid biopsies to conventional diagnostics and response measurements as well as studies showing that liquid biopsies can be used to switch therapies leading to improved outcomes. However, liquid biopsies using ctDNA for specific markers such as EGFR, ALK, ROS1 or RET have clinical applications because specific drugs are available.

Original languageEnglish
Article number3704
Number of pages9
JournalApplied Sciences
Volume10
Issue number11
Publication statusPublished - Jun-2020

    Keywords

  • liquid biopsies, CTC, ctDNA, NSCLC, CIRCULATING TUMOR-CELLS, PROGNOSTIC-SIGNIFICANCE, DIAGNOSTIC BIOMARKER, SURVIVAL, EGFR, CHEMOTHERAPY, PROGRESSION, MUTATIONS, DOCETAXEL, OUTCOMES

Download statistics

No data available

ID: 129777429